Time to Reconsider Intra-cellular Therapies Inc (NASDAQ:ITCI) After Less Short Sellers?

Investors sentiment increased to 1.4 in Q2 2019. Its up 0.07, from 1.33 in 2019Q1. It improved, as 15 investors sold Intra-Cellular Therapies, Inc. shares while 25 reduced holdings. 13 funds opened positions while 43 raised stakes. 34.58 million shares or 6.28% less from 36.90 million shares in 2019Q1 were reported.
New York State Common Retirement Fund accumulated 43,900 shares. Ameriprise invested in 0% or 11,500 shares. 39,914 are owned by Barclays Public Limited Company. Voya Mngmt Limited Liability Co reported 19,478 shares stake. 33,761 are owned by Invesco Ltd. Nuveen Asset Mgmt Limited Liability stated it has 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Bnp Paribas Arbitrage Sa, New York-based fund reported 6,019 shares. The Massachusetts-based Fmr Ltd Limited Liability Company has invested 0.01% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Parametric Port Associates Lc reported 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Meeder Asset reported 1,878 shares. Alpine Woods Capital Invsts Limited Liability holds 18,100 shares or 0.05% of its portfolio. Jpmorgan Chase & Commerce owns 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 210,531 shares. Natl Bank Of America De reported 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Thrivent Fincl For Lutherans has 67,430 shares for 0% of their portfolio. General Invsts Co Incorporated, a New York-based fund reported 299,942 shares.

Since May 14, 2019, it had 4 buys, and 0 selling transactions for $9.29 million activity.

The stock of Intra-cellular Therapies Inc (NASDAQ:ITCI) registered a decrease of 0.1% in short interest. ITCI’s total short interest was 4.68 million shares in October as published by FINRA. Its down 0.1% from 4.68 million shares, reported previously. With 643,400 shares average volume, it will take short sellers 7 days to cover their ITCI’s short positions.

The stock decreased 2.21% or $0.17 during the last trading session, reaching $7.76. About 607,197 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 57.38% since October 12, 2018 and is downtrending. It has underperformed by 57.38% the S&P500.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company has market cap of $427.87 million. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 2 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intra-Cellular Therapies has $2100 highest and $1600 lowest target. $18.50’s average target is 138.40% above currents $7.76 stock price. Intra-Cellular Therapies had 4 analyst reports since May 16, 2019 according to SRatingsIntel. JMP Securities maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) rating on Thursday, August 8. JMP Securities has “Market Outperform” rating and $2100 target.

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: Seekingalpha.com which released: “Buying Intra-Cellular Therapies On The Dip: Investment Thesis – Seeking Alpha” on July 16, 2019, also Seekingalpha.com with their article: “Microcaps mostly among midday movers – Seeking Alpha” published on July 08, 2019, Finance.Yahoo.com published: “Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock? – Yahoo Finance” on April 29, 2019. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: Fool.com and their article: “Intra-Cellular Therapies, Inc. (ITCI) Q1 2019 Earnings Call Transcript – Motley Fool” published on May 08, 2019 as well as Globenewswire.com‘s news article titled: “Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results – GlobeNewswire” with publication date: August 07, 2019.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.